SeaStar Medical (NASDAQ:ICU) Raised to “Hold” at Wall Street Zen

SeaStar Medical (NASDAQ:ICU) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of SeaStar Medical in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, SeaStar Medical has an average rating of “Sell”.

SeaStar Medical Stock Down 6.2%

Shares of NASDAQ ICU opened at $2.26 on Friday. SeaStar Medical has a 12 month low of $2.20 and a 12 month high of $30.70. The company has a market cap of $8.14 million, a price-to-earnings ratio of -0.14 and a beta of -1.00. The business has a fifty day simple moving average of $3.30 and a 200-day simple moving average of $5.81.

SeaStar Medical (NASDAQ:ICU) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($1.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.50) by $0.20. SeaStar Medical had a negative return on equity of 414.50% and a negative net margin of 1,551.08%.The firm had revenue of $0.18 million for the quarter, compared to analysts’ expectations of $0.25 million.

Institutional Trading of SeaStar Medical

Hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd increased its stake in shares of SeaStar Medical by 395.4% during the 2nd quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock worth $26,000 after purchasing an additional 48,674 shares during the last quarter. Trinity Financial Advisors LLC boosted its holdings in SeaStar Medical by 233.3% in the third quarter. Trinity Financial Advisors LLC now owns 50,000 shares of the company’s stock worth $28,000 after purchasing an additional 35,000 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in SeaStar Medical during the third quarter worth $102,000. 1.69% of the stock is owned by hedge funds and other institutional investors.

About SeaStar Medical

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.